Hepatitis C drugs hit by incompatibility warnings Gilead’s hepatitis C drugs Harvoni and Sovaldi and Bristol-Myers Squibb’s Daklinza have been hit by warnings from drug regulators regarding their incompatibility with amiodarone.…
Antihistamine could be used as a cheaper hepatitis C therapy, study suggests An anti-allergy treatment is effective in treating hepatitis C virus, a study has found, raising hopes of an affordable weapon in the fight against the virus. …
Rolling out hepatitis C treatments will be costly The new generation of heptatitis C antivirals is highly effective, but the drugs’ expense will put pressure on healthcare providers.…
Latest advances in hepatitis C therapy The availability of new protease inhibitors is revolutionising the treatment of hepatitis C virus infection.…
EU approval of AbbVie’s hepatitis C combination therapies challenges Gilead’s Harvoni A highly effective therapy for patients with hepatitis C is being launched by AbbVie in the EU over the next couple of months in direct competition with another treatment made by Gilead that was approved in 2014 and is now being rolled out. …
Beethoven’s musical electrocardiogramsCould Beethoven have suffered from cardiac arrhythmia? His music suggests he could have.…
2014: The Pharmaceutical Journal’s news in review Looking back at some of the biggest news stories from the past year. …
Community pharmacists could screen at-risk groups for liver disease According to The Lancet’s commission, community pharmacists could play a key role in helping to improve liver disease services in primary care, say hepatology specialists.…
Novel drug could eliminate hepatitis C in 15 years Daclatasvir is estimated to cure chronic hepatitis C infection in up to 99% of cases when used in combination with other drugs.…
